Clinical Trials Logo

Filter by:
NCT ID: NCT03600051 Completed - Aortic Stenosis Clinical Trials

Automated Phonocardiography Analysis in Adults

Start date: December 10, 2015
Phase:
Study type: Observational

Background: Computer aided auscultation in the differentiation of pathologic (AHA class I) from no- or innocent murmurs (AHA class III) via artificial intelligence algorithms could be a useful tool to assist healthcare providers in identifying pathological heart murmurs and may avoid unnecessary referrals to medical specialists. Objective: Assess the quality of the artificial intelligence (AI) algorithm that autonomously detects and classifies heart murmurs as either pathologic (AHA class I) or as no- or innocent (AHA class III). Hypothesis: The algorithm used in this study is able to analyze and identify pathologic heart murmurs (AHA class I) in an adult population with valve defects with a similar sensitivity compared to medical specialist. Methods: Each patient is auscultated and diagnosed independently by a medical specialist by means of standard auscultation. Auscultation findings are verified via gold-standard echocardiogram diagnosis. For each patient, a phonocardiogram (PCG) - a digital recording of the heart sounds - is acquired. The recordings are later analyzed using the AI algorithm. The algorithm results are compared to the findings of the medical professionals as well as to the echocardiogram findings.

NCT ID: NCT03590444 Completed - Clinical trials for Diabetic Retinal Edema

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

Start date: April 2, 2017
Phase: Phase 4
Study type: Interventional

Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.

NCT ID: NCT03585270 Completed - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

REACT
Start date: February 3, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.

NCT ID: NCT03584607 Completed - Insulin Resistance Clinical Trials

Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension

Start date: December 20, 2017
Phase:
Study type: Observational

Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. In this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.

NCT ID: NCT03583632 Completed - Epiretinal Membrane Clinical Trials

Visual Acuity and Optical Coherence Tomography One Year After Peeling of Epiretinal Membranes

Start date: February 1, 2018
Phase:
Study type: Observational

Improvement in visual acuity and retinal anatomy one year after surgery is assessed and compared to data preoperative and 3 months after surgery

NCT ID: NCT03580369 Completed - Clinical trials for Chronic Spontaneous Urticaria

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Start date: October 17, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo. The study population consisted of 1,072 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines. This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.

NCT ID: NCT03574597 Completed - Obesity Clinical Trials

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

SELECT
Start date: October 24, 2018
Phase: Phase 3
Study type: Interventional

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

NCT ID: NCT03570151 Completed - Clinical trials for All Health Problems Occurring During a Music Festival

Medical Care at a Mass-gathering Music Festival

Start date: April 1, 2018
Phase:
Study type: Observational

Key Objective is to describe Patient Presentation Rate and Transport to Hospital rate at an Austrian Music Festival. If significant changes in specific incidence rates are found, a causal explanation will be looked for.

NCT ID: NCT03565289 Completed - Clinical trials for Indication for Prostate Biopsy Due to Suspected Prostate Cancer

PRospective Prostate biOmarker Study

PROPOSe
Start date: August 14, 2018
Phase:
Study type: Observational

• Correlation of a glycoprotein panel with prostate biopsy outcome and PCa aggressiveness

NCT ID: NCT03563547 Completed - Clinical trials for Heterozygous Familial Hypercholesterolemia

Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia

SOYFIT
Start date: September 3, 2009
Phase: N/A
Study type: Interventional

Familial hypercholesterolemia (FH) is an inheritable, autosomal dominant disorder leading to pathologically increased levels of low-density-lipoprotein cholesterol (LDL-C). Dietary treatment remains an important tool in the management of affected children even after the decision for the initiation of pharmacotherapy is made. However, little evidence is available on the beneficial effects of diets low in saturated fat and cholesterol and diets enriched with soy in children affected with FH. Based on these previous findings we hypothesize that the LDL-C lowering effect of a fat-modified diet could be further increased by the addition of soy-protein in children affected with HeFH.